Incidence of melanoma has been increasing, being able to metastasize to any organ with variable clinical presentation and evolution.
Publications
FDA grants priority review to tebentafusp for metastatic uveal melanoma
Tebentafusp-tebn (Kimmtrak, Immunocore) — the only FDA-approved treatment for this indication — is the first T-cell receptor therapeutic to receive regulatory approval.
FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma
The FDA has approved tebentafusp-tebn (Kimmtrak) for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.
FDA grants fast track designation to BNT111 for advanced melanoma
BNT111 (BioNTech) — an investigational cancer immunotherapy — uses a fixed combination of mRNA-encoded, tumor-associated antigens designed to activate a precise and strong immune response against cancer.